Mineralocorticoid receptor antagonists and aldosterone synthase inhibitors: agent comparison with implications for clinical practice and trial design
Résumé
JPF has received research support from AstraZeneca, Boehringer-Ingelheim, Novartis, Amgen, Salamandra and Bial. JSN has received consulting or speaker fees fromAstraZeneca, BIAL, Boehringer Ingelheim, Lilly, Menarini, Merck, NovoNordisk and Sanofi. FZ has received personal fees from Applied Therapeutics, Bayer, Betagenon, Biopeutics, Boehringer, BMS, Cambrian, Cardior, Cellprothera, Cereno pharmaceutical, CVRx, Merck, Northsea, Otsuka, Owkin, Polygon, and Salubris; has stock options at G3Pharmaceutical, has equities at Cereno pharmaceutical, and is the founder of Cardiovascular Clinical Trialists (CVCT). BP is consultant for Bayer, Boehringer Ingelheim, Lexicon, Anacardio, Vifor*, scpharmaceuticals*, SQinnovations*, g3pharmaceuticals*, Sarfez pharmaceuticals*, Kbp biosciences*, Cereno scientific*, Prointel*, sea star medical* (*= stock/stock options), US patent 9931412 site specific delivery of Eplerenone to the myocardium, US patent pending 63\045,783 histone modulating agents for the prevention and protection of organ damage. The remainder of the authors report no conflicts of interest regarding the content of this manuscript.
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|---|
| Licence |

